Adept Medical announced the launch of the IR Platform, designed as an over-patient work surface for vascular and interventional radiology. The platform provides clinical benefits to the current practice of laying procedural equipment over the patient’s legs by offering a stable, radiolucent, height- and length-appropriate solution for femoral artery access procedures. It offers a stable solution for catheter/guide wire manipulation, with a large work area for equipment.
May 16, 2017 — Here is a list of the late-breaking clinical trials presented at the Heart Rhythm Society (HRS) 2017 ...
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal ...
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
This video, provided by Medtronic, demonstrates the implantation of Micra transcatheter pacing system (TPS). The device ...
Soundwaves LLC recently announced the diversification of its portable ultrasound services beyond obstetrics and gynecology to other medical disciplines, including cardiology, and the expansion of its operations from South Florida to the Mid-Atlantic.
May 15, 2017 – The Heart Rhythm Society (HRS) in joint partnership with several other electrophysiology societies issued ...
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
A first-of-its-kind study discovered that women and minorities who underwent a percutaneous coronary intervention (PCI) are at greater risk of experiencing recurrent cardiac events within the first year after their procedure compared to Caucasian men. Those outcomes may be attributable to their race, gender and socioeconomic status rather than the PCI procedure itself. Results from “Interaction Effects of Race/Ethnicity and Sex on Outcomes after PCI: A Subanalysis of the PLATINUM Diversity study” were presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions May 10-13 in New Orleans.
May 15, 2017 — The Heart Rhythm Society (HRS) released a first-of-its-kind consensus statement in the United States on ...
For patients who undergo transcatheter aortic valve replacement (TAVR), their risk factors, not the type of valve used, determined their 30-day post-TAVR outcomes. Results from “Impact of valve design and bivalirudin vs. unfractionated heparin for anticoagulation in transcatheter aortic valve replacement: Results from the BRAVO-3 trial” were presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions, May 10-13 in New Orleans.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
In a large-scale analysis of percutaneous coronary intervention (PCI)-related hospitalizations, people admitted to the hospital on a weekend were twice more likely to die than those hospitalized on a weekday. Results from “Weekend Effect for Percutaneous Coronary Intervention Admissions: A 10-Year U.S. Experience” were presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions, May 10-13 in New Orleans.
May 15, 2017 – The U.S. Food and Drug Administration (FDA) has granted market clearance Medtronic’s portfolio of ...
A study in 65 countries has revealed low adoption of International Atomic Energy Agency (IAEA) recommendations to reduce nuclear cardiology radiation exposure. The research was presented at ICNC 2017, May 7-9 in Vienna Austria, by Edward Hulten, M.D., a cardiologist at the Walter Reed National Military Medical Center, Bethesda, Md.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and effectiveness of a new stent to treat patients with coronary heart disease who are at higher risk for bleeding.
An analysis of data from the entire development program consisting of three trials assessing the feasibility of using a stem cell therapy (CD34+ cells) to treat patients with refractory angina showed a statistically significant improvement in exercise time as well as a reduction in mortality. Results from “CD34+ Stem Cell Therapy Improves Exercise Time and Mortality in Refractory Angina: A Patient Level Meta-Analysis” were presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions, May 10-13 in New Orleans.
May 12, 2017 – New study proves safety of novel, wireless pacing system, WiSE CRT (Wireless Stimulation Endocardially ...